Mr. Jeffrey Bacha reports

RAKOVINA THERAPEUTICS ANNOUNCES RESULTS FROM 2023 ANNUAL GENERAL MEETING

Rakovina Therapeutics Inc. has released the results of voting at its 2023 annual general meeting of shareholders held on June 28, 2023.

All four members of the company's board of directors named as nominees in its management information circular were re-elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia and Michael Liggett.

Additional voting results from the meeting include: (i) the shareholders approving the appointment of Davidson & Company LLP as the company's auditor until the next annual meeting; and (ii) the shareholders approving the company's existing omnibus equity incentive plan as set out in the circular.

About Rakovina Therapeutics Inc.

Rakovina is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the U.S. Food and Drug Administration, and similar international regulatory agencies.